The blood glucose monitoring and data management company AgaMatrix and the digital health assistant developer LifeWallet announced a collaboration to bring AgaMatrix’s connected blood glucose monitoring solutions together with LifeWallet’s apps for health risk assessment and follow-up care, for improved outcomes in population health management.
Novo Nordisk and Glooko announced that the new Cornerstones4Care Powered by Glooko app (C4C app) is now available to help people more effectively manage their diabetes.
Merck in partnership with Pfizer Inc. announced that two Phase 3 studies of ertugliflozin met their primary endpoints.
Smart Meter LLC received 510(k) clearance from FDA and CE Mark in Europe to market the company’s iGlucose Blood Glucose Monitoring System.
A review about two promising applications of digital data to improve patient marketing, plus a third “low-hanging fruit” tactic most brands should explore.
2016 Annual Report: Top 200 Medicines
Angiogenesis, August 2016, Autoimmune Diseases, Autoimmune Disorders, Biologics, Biosimilars, Breast Cancer, Cervical Cancer, Colorectal Cancer, Crohn's Disease, Diabetes, FDA, FDA/Regulatory, Hepatitis C, Inflammatory Diseases, Kidney Cancer, Launches, Lung Cancer, Monoclonal Antibodies, Oncology, Ovarian Cancer, Patents, Plaque Psoriasis, Product Launches, Psoriasis, Rheumatoid Arthritis, Sales, Special Reports, Therapeutics, Ulcerative ColitisAbbVie’s biologic therapy Humira for autoimmune diseases was the worldwide prescription-drug sales leader in 2015 for the fourth consecutive calendar term.
Special Feature: Pharma Leaders of Innovation
Advisory Panels, Antibiotics, August 2016, Big Pharma, Blood Thinner, Brands, Cloud, Diabetes, DTC, Epilepsy, FDA, FDA/Regulatory, Foundations, Gender diversity, Generics, Healthcare Communications Agencies, Healthcare Communications Networks, Healthcare Practitioners, Innovation, Mental Health, Neuroscience, Opioids, Pharma, Pharma Leaders of Innovation special feature, Product Launches, Sales & Marketing, Schizophrenia, Specialty Pharma, TechnologyMed Ad News’ first edition of the Pharma Leaders of Innovation special feature showcases two CEOs focusing outside the big pharma box and an agency tech leader.
To reach payer audiences, companies have to focus far less on promotional tactics and show the value of their products.
2016 Annual Report: Top 10 Pipelines
"Bad" LDL Cholesterol, Alzheimer's Diseases, Approvals, Big Pharma, Biologics License Application (BLA), Biosimilars, Biotech, Biotech/Biopharma, Biotechnology, Bispecific CD19-directed CD3 T cell engager (BiTE) antibodies, Blockbusters, Blood Cancers, Breakthrough Designation, Breakthrough Therapy, Breakthrough Therapy Designation, Breakthrough Therapy Designation, Cells, Chimeric Antigen Receptor T Cell Therapy (CART), Cholesterol, Chronic Lymphocytic Leukemia, Clinical Trials, Collaboration, Collaborations, Collaborations, Cystic Fibrosis, Deals, Diabetes, DNA, EGFR Inhibitors, Europe, European Commission, FDA, FDA/Regulatory, February 2016, Glucagon-Like Peptide-1 (GLP-1) Analogs, Immune Response, Immune System, Immune Systems, Immunotherapies, Influenza, Inhalers, Issue Archives, Mantle Cell Lymphoma (MCL), Monoclonal Antibodies, Multiple Myeloma, NDA, Neuroscience, New Drug Application (NDA), New Molecular Entities, Non-Small Cell Lung Cancer, Oncology, Pain, Parkinson's, Parkinson's Disease, Plaque Psoriasis, Potential Blockbusters, Psoriasis, R&D, Sales, SGLT2 Inhibitors, Special Reports, Specialty Therapy, Technology, TGF-Beta Inhibitors, The New England Journal of Medicine (NEJM), Therapeutics, Top 10 Pipelines, Transforming Growth Factor-beta (TGFb), Type 1 Diabetes, Type 2 Diabetes, Vaccines, Waldenstrom’s macroglobulinemiaThe pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.
Closely held Intarcia Therapeutics Inc. said its implantable drug-delivery pump proved superior to Merck MRK -0.42 % & Co.’s top-selling drug Januvia in helping diabetes patients control blood sugar in […]